Kronos Bio Stock
Kronos Bio is dedicated to the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets.
Sign up today and learn more about Kronos Bio Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Kronos Bio Stock
Kronos Bio is dedicated to the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets. It develops therapies that modulate historically undruggable targets. The company leverages deep capabilities in high-throughput small-molecule microarrays (SMM), targeted protein degradation, and cancer biology in order to identify potent and selective compounds against transcription factors and other central drivers of oncogenic signaling. . In 2017, Angela Koehler, Christopher Wilfong, and Joshua A. Kazam established Kronos Bio in San Mateo California.
Vice President, Program Management
Vice President, Pharmacology
Douglas C. Saffran
President & Chief Executive Officer
Chief Operating Officer and Founder
Vice President, Clinical Operations
Vice President, Biology
Vice President, Chemistry
Chief Medical Officer & Executive Vice President, Clinical Development
Chief Business Officer
Philip P. Gutry